April 28, 2026 02:00 ET  | Source: Boehringer Ingelheim Limited Ingelheim, Germany. Boehringer Ingelheim today announced positive topline results from the Phase III SYNCHRONIZE-1 trial, in which survodutide (BI 456906) met the co-primary endpoints using both the efficacy and treatment-regimen estimands.*† Adults living with obesity or overweight, without type 2 diabetes, who were treated with survodutide experienced sustained weight

Global CDMO recognized for exceptional quality systems and regulatory track record; named finalist in Excellence in Client Service & Partnership and Manufacturing Operations categories April 27, 2026 11:59 ET  | Source: AGC Biologics, Inc. SEATTLE, April 27, 2026 (GLOBE NEWSWIRE) — AGC Biologics, your friendly CDMO expert, is the 2026 recipient of the Fierce Outsourcing Award for

April 26, 2026 23:30 ET  | Source: Dark Horse Consulting Group WALNUT CREEK, Calif. and SUZHOU, China, April 26, 2026 (GLOBE NEWSWIRE) — Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, and Porton Advanced, a premier contract development and manufacturing organization (CDMO) specializing in Advanced Therapy Medicinal Products (ATMPs),

– Regulatory Filing in Japan Planned Following Clinical Trial Completion – April 24, 2026 08:00 ET  | Source: Kyowa Kirin TOKYO and SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) — Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) and Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) today announced the first patient has been dosed in a Japanese Phase 2

April 23, 2026 09:00 ET  | Source: Royal Philips April 23, 2026   Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced the launch of the next-generation Bridge Plus Occlusion Balloon, designed to help electrophysiology teams rapidly control bleeding and stabilize patients during rare but life-threatening superior vena cava (SVC) tears in

April 22, 2026 09:00 ET  | Source: Royal Philips April 22, 2026 Clearances for Rembra CT, Rembra RT, and Areta RT enable high-throughput imaging at scale and elevate precision across the cancer care pathway Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received 510(k) clearance from the

April 21, 2026 17:30 ET  | Source: Zymeworks Inc. VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced results from the dose-escalation part of the Phase 1 study for ZW191, a folate

April 21, 2026 08:00 ET  | Source: Smith & Nephew UK Ltd Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces further compelling evidence from a multicenter, randomized controlled trial highlighting the clinical superiority of its CARTIHEAL AGILI-C Cartilage Repair Implant recently published in the American Journal of Sports Medicine (AJSM). The CARTIHEAL AGILI-C Cartilage Repair Implant

April 21, 2026 06:00 ET  | Source: Dark Horse Consulting Group WALNUT CREEK, Calif. and TOKYO, April 21, 2026 (GLOBE NEWSWIRE) — Dark Horse Consulting Group (“DHCG” or “the Group”) today announced the acquisition of CJ PARTNERS (“CJP”), a distinguished consulting and advisory firm specializing in bridging the gap between Western and Eastern therapeutic developers and stakeholders

April 20, 2026 19:00 ET  | Source: Essential Pharma 英国 – 2026 年 4 月 21 日 – Essential Pharma 旗下专注于研发阶段资产的公司 Renaissance Pharma Limited 今天宣布，美国食品和药品管理局 (FDA) 已授予其新型抗 GD2 单克隆抗体 Daretabart (hu1418K322A) 快速通道认定资质，这种正在开发的药物用于治疗罕见儿童癌症 — 高危神经母细胞瘤 (HRNB)。此项认定旨在解决 HRNB 领域存在的重大未满足医疗需求，将有助于该公司在研发过程中与 FDA 更频繁地沟通互动，并使其具备获得加速审评和滚动审评的资格。 公司同时确认已获得 FDA 的新药临床研究许可，即将在美国启动针对 HRNB 复发或难治性患儿的 SHINE II/III 期临床试验。Daretabart (hu1418K322A) 用于 SHINE 试验的第一个商业化规模药品生产质量管理规范 (GMP) 批次的生成也已成功完成。 Daretabart (hu1418K322A) 由 Renaissance Pharma

April 20, 2026 17:00 ET  | Source: Junshi Biosciences SHANGHAI, April 20, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that early clinical results from four studies across its innovative pipeline were presented at

April 20, 2026 08:00 ET  | Source: Boehringer Ingelheim Limited Ingelheim, Germany, and London, UK – Boehringer Ingelheim today announced the expansion of its global Computational Innovation footprint with the launch of a new center for AI and machine learning in King’s Cross, London, UK, part of the Knowledge Quarter ecosystem. As the company continues to innovate and expand

April 17, 2026 16:01 ET  | Source: Adagene Inc. Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%, respectively by Investigator per HCC-specific Modified RECIST v1.1) as 1L therapy in a Phase 1b/2 trial in locally advanced or metastatic

April 17, 2026 15:00 ET  | Source: Zymeworks Inc. VANCOUVER, British Columbia, April 17, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced six poster presentations featuring new preclinical data from its antibody-drug conjugate (ADC) and payload

April 16, 2026 09:00 ET  | Source: Royal Philips April 16, 2026 Combining always-on spectral imaging with AI reconstruction to deliver enhanced levels of image quality, efficiency, and clinical insight across radiology, cardiology, and oncology Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received U.S. Food and Drug